Supplementary table 1.docx (14.63 kB)
Download fileSafety of megadose meropenem in the empirical treatment of nosocomial sepsis: a pilot randomized clinical trial - supplementary table
dataset
posted on 2023-05-05, 13:46 authored by Mohammadreza Salehi, Farah Rezazade-Moayed, Hossein Khalili, Homa Hemati, Nasser Aghdami, Mohadese Dashtkoohi, Mohammad Dashtkoohi, Mohammad-Taghi Beig-Mohammadi, Masoud Ramezani, Mahboobeh Hajiabdolbaghi, Samrand Fattah-GhaziObjective: To evaluate the safety of megadose meropenem as empirical treatment of nosocomial sepsis.
Materials & methods: Critically ill patients diagnosed with sepsis received either high-dose (2 g every 8 h)
or megadose (4 g every 8 h) meropenem as an intravenous infusion over 3 h. Results: A total of 23 patients
with nosocomial sepsis were eligible and included in the megadose (n = 11) or high-dose (n = 12) group.
No treatment-related adverse events were observed during a 14-day follow-up. Clinical response was also
comparable between the groups. Conclusion: Megadose meropenem may be considered for empirical
treatment of nosocomial sepsis without serious concern regarding its safety.
